ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $8.50 Consensus Price Target from Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have received a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $8.50.

ALXO has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a research note on Wednesday, December 18th. Jefferies Financial Group lowered ALX Oncology from a “buy” rating to a “hold” rating and cut their price objective for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Wednesday, December 18th.

Insiders Place Their Bets

In related news, Director Rekha Hemrajani bought 30,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average cost of $1.55 per share, with a total value of $46,500.00. Following the purchase, the director now directly owns 33,000 shares of the company’s stock, valued at $51,150. The trade was a 1,000.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 33.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ALXO. Point72 Asset Management L.P. purchased a new position in ALX Oncology during the second quarter worth about $1,834,000. GSA Capital Partners LLP acquired a new position in ALX Oncology in the third quarter valued at approximately $88,000. Marshall Wace LLP lifted its holdings in ALX Oncology by 423.0% in the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after acquiring an additional 514,133 shares during the last quarter. SG Americas Securities LLC grew its position in ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after acquiring an additional 6,888 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after acquiring an additional 5,200 shares during the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $1.62 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The firm has a fifty day moving average of $1.52 and a 200 day moving average of $3.00. The firm has a market cap of $85.44 million, a PE ratio of -0.54 and a beta of 1.04. ALX Oncology has a one year low of $1.19 and a one year high of $17.83.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.